What Drives Deprescribing in Community Palliative Care
This qualitative synthesis maps the patient, clinician, and system factors that determine whether potentially inappropriate medications are stopped in community-dwelling palliative patients, offering pharmacists a framework for intervention design.
📅 Journal publication: Oct 2026(online Jul 31, 2026)·Last updated: Oct 7, 2026
Optimizing deprescribing enhances life quality for palliative patients.
Deprescribing potentially inappropriate medications in palliative care improves patient outcomes and reduces adverse health effects. The review identified four themes influencing deprescribing: patient values, communication strategies, organizational factors, and system-level prerequisites. A multidimensional approach incorporating patient-centered care, shared decision-making, and collaborative interdisciplinary efforts is essential for effective deprescribing. Optimizing deprescribing in palliative care requires attention to patient values, communication, and organizational support.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.